These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 25388274)
1. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. Garès V; Andrieu S; Dupuy JF; Savy N Stat Med; 2015 Feb; 34(4):541-57. PubMed ID: 25388274 [TBL] [Abstract][Full Text] [Related]
2. Comparison of survival distributions in clinical trials: A practical guidance. Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788 [TBL] [Abstract][Full Text] [Related]
3. Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. Scherrer B; Andrieu S; Ousset PJ; Berrut G; Dartigues JF; Dubois B; Pasquier F; Piette F; Robert P; Touchon J; Garnier P; Mathiex-Fortunet H; Vellas B J Nutr Health Aging; 2015 Dec; 19(10):1009-11. PubMed ID: 26624212 [TBL] [Abstract][Full Text] [Related]
4. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. Royston P; B Parmar MK Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820 [TBL] [Abstract][Full Text] [Related]
5. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. Uno H; Tian L; Claggett B; Wei LJ Stat Med; 2015 Dec; 34(28):3680-95. PubMed ID: 26194988 [TBL] [Abstract][Full Text] [Related]
6. Sample size determination for comparing more than two survival distributions. Ahnn S; Anderson SJ Stat Med; 1995 Oct; 14(20):2273-82. PubMed ID: 8552903 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics. Yang P; Fleming TR J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070 [TBL] [Abstract][Full Text] [Related]
8. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies. Hasegawa T Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461 [TBL] [Abstract][Full Text] [Related]
9. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. Royston P; Parmar MK Trials; 2014 Aug; 15():314. PubMed ID: 25098243 [TBL] [Abstract][Full Text] [Related]
17. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model. Xiong X; Wu J Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138 [TBL] [Abstract][Full Text] [Related]
18. Unobserved covariates in the two-sample comparison of survival times: a maximum efficiency robust test. Broët P; Moreau T; Lellouch J; Asselain B Stat Med; 1999 Jul; 18(14):1791-800; discussion 1801. PubMed ID: 10407249 [TBL] [Abstract][Full Text] [Related]
19. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. Hasegawa T Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855 [TBL] [Abstract][Full Text] [Related]
20. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials. Horiguchi M; Cronin AM; Takeuchi M; Uno H Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]